Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2017-03, Vol.31 (3), p.775-775
Main Authors: Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F
Format: Article
Language:English
Subjects:
Erratum
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Correction to: Leukemia (2016) 30, 1701-1707; doi:10.1038/leu.2016.148 Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2016.323